Investment
Features
FeesSafety
Academy
More
Pluang+

Compare RLX Technology Inc (RLX) vs Twist Bioscience Corp (TWST) Price & Performance

RLX Technology IncTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

RLX Technology Inc vs Twist Bioscience Corp — how do they compare? RLX Technology Inc trades at $2.02 (market cap $2.42B), while Twist Bioscience Corp trades at $122.96 (market cap $7.72B). The key difference: Twist Bioscience Corp is far larger — about 3.2× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

RLXTWST
Market Cap
$2.42B$7.72B
Sector
TechnologyHealth
52-Week High
$2.73$124.88
52-Week Low
$1.79$24.16
Enterprise Value
$1.04B$7.65B
Dividend Yield
5.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

RLX Technology Inc

RLX Technology trades at $2.02, up 1.0% with bearish technical signals despite recent earnings misses. The company maintains strong profitability with 22.47% net margins and international expansion driving revenue growth from $3.62B to $4.4B. Cash flow trends show operational strength but negative net cash flow. Analyst coverage remains limited with a single hold rating.

RLX faces execution risks from international integration while trading at reasonable valuations (P/E 17.96). The upcoming Q2 2026 earnings on August 14 will be crucial for validating growth trajectory amid competitive and regulatory pressures in the global e-vapor market.

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $125.13, up 0.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q3 2026 revenue of $118.4 million, up 23% year-over-year, beating estimates, but posted a net loss. Revenue growth is strong, yet profitability remains elusive with negative margins. Recent news highlights an upsized $300 million public offering and expanding AI drug discovery pipeline.

Outlook is mixed: robust revenue growth and analyst optimism (78.57% buy ratings) support upside, but persistent losses, cash burn, and high valuation multiples pose significant risks. The stock's proximity to resistance at $126 suggests near-term volatility. Investors should weigh growth potential against financial sustainability concerns.

Returns comparison

Trailing returns across standard periods

About RLX Technology Inc

RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.

Read more on RLX

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST